158 related articles for article (PubMed ID: 10605717)
1. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system.
Blasi F
Thromb Haemost; 1999 Aug; 82(2):298-304. PubMed ID: 10605717
[No Abstract] [Full Text] [Related]
2. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
Ueshima S; Fukao H; Okada K; Matsuo O
Thromb Res; 2004; 113(1):41-9. PubMed ID: 15081564
[TBL] [Abstract][Full Text] [Related]
4. The urokinase receptor and cell migration.
Blasi F
Semin Thromb Hemost; 1996; 22(6):513-6. PubMed ID: 9122717
[TBL] [Abstract][Full Text] [Related]
5. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis.
Nonaka T; Kikuchi H; Ikeda T; Okamoto Y; Hamanishi C; Tanaka S
J Rheumatol; 2000 Apr; 27(4):997-1004. PubMed ID: 10782829
[TBL] [Abstract][Full Text] [Related]
7. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
Chavakis T; Kanse SM; May AE; Preissner KT
Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
[TBL] [Abstract][Full Text] [Related]
8. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?
Blasi F
Immunol Today; 1997 Sep; 18(9):415-7. PubMed ID: 9293155
[No Abstract] [Full Text] [Related]
9. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
Li H; Dong S; Zeng Y
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
[TBL] [Abstract][Full Text] [Related]
11. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
Reuning U; Magdolen V; Hapke S; Schmitt M
Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator and receptor in osteoarthritis.
Serni U; Fibbi G; Anichini E; Zamperini A; Pucci M; Mannoni A; Matucci A; Benucci M; Del Rosso A; Del Rosso M
J Rheumatol Suppl; 1995 Feb; 43():120-2. PubMed ID: 7752114
[TBL] [Abstract][Full Text] [Related]
13. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Takahashi T; Suzuki K; Ihara H; Mogami H; Kazui T; Urano T
Semin Thromb Hemost; 2005 Jun; 31(3):356-63. PubMed ID: 16052409
[TBL] [Abstract][Full Text] [Related]
15. Modulation of sympathetic activity by tissue plasminogen activator is independent of plasminogen and urokinase.
Schaefer U; Vorlova S; Machida T; Melchor JP; Strickland S; Levi R
J Pharmacol Exp Ther; 2007 Jul; 322(1):265-73. PubMed ID: 17429057
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
[TBL] [Abstract][Full Text] [Related]
17. [Navigational receptors in cells: physiological role and mechanisms of functioning].
Tkachuk VA; Semina EV; Rubina KA; Sysoeva VIu; Kalinina NI; Stambol'skiĭ VD; Parfenova EV
Fiziol Zh (1994); 2011; 57(5):80-3. PubMed ID: 22276315
[No Abstract] [Full Text] [Related]
18. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
Bajou K
Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of signaling through urokinase receptor and the cellular response.
Koshelnick Y; Ehart M; Stockinger H; Binder BR
Thromb Haemost; 1999 Aug; 82(2):305-11. PubMed ID: 10605718
[No Abstract] [Full Text] [Related]
20. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]